Emergent BioSolutions has announced only two acquisitions in the past 5 years.
With the acquisition of Trubion, Emergent BioSolutions strengthened its oncology product pipeline and also broadened its monoclonal antibody therapeutic capabilities.
With its strategic acquisition of Cangene recently in December 2013, Emergent Biosolutions accelerated its biodefense portfolio by adding marketed therapeutics.
The company looks to enter into M&A agreements for licensed marketed products to expand their business in specialty markets.
Abstracted from: Partnering Agreements with Emergent BioSolutions 2009-2014
View the full details of the deals at Current Agreements (subscription required)
Emergent BioSolutions M&A at Current Agreements
Full details on each deal can be found at CurrentAgreements (subscription required)
Related reports from Current Partnering
Report: Partnering Agreements with Emergent BioSolutions 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Report: Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics
Available resources for deal coverage for Emergent BioSolutions
Read: more on Emergent BioSolutions company profile, recent partnering, M&A and financing news and articles
Report: Finding Biopharma Licensing and Collaboration Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk